China's quest to get the yuan recognized as a reserve currency by the International Monetary Fund (IMF) could trickle down to affect gold, says Jim Rickards, best-selling author of 'Currency Wars' and 'The Death of Money'. Rickards explains that there is a current peg between the U.S. dollar and the Chinese yuan, 'the currency wars are being fought around the world, but there is a sort of a lull in the fighting between the U.S. and China right now.' Rickards explains that since the U.S. has veto powers at the IMF, China is on its best behavior. 'We define best behavior as not cheapening the yuan,' Rickards says. The short-term ramification is that the dollar-yuan peg will hold throughout the year. 'The Chinese are not undercutting the U.S. - so the dollar may maintain that value,' he says, adding that the higher U.S. dollar could keep gold prices suppressed. Rickards does foresee the dollar eventually correcting. 'The strong dollar is killing the U.S. economy, this is part of the currency wars... [A]ll this is the opposite of what the Fed wants - the Fed wants more growth, nominal growth and real growth, and the only way to get that is a cheap dollar.' China is also expected to receive approval from its central bank for a yuan-denominated gold fix, with a potential for an announcement as early as next week.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.